{"entity":{"type":"insider","cik":"0001876996","url":"/insider/0001876996","json_url":"/insider/0001876996.json","name":"Waltermire Robert E.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":30,"n_filings":10,"first":"2023-03-02","last":"2025-03-07","span_basis":"filed_date"},"name_variants":[{"name":"Waltermire Robert E.","source":"filing","n_filings":10,"first_seen":"2023-03-02","last_seen":"2025-03-07"}],"transactions":[{"id":5111132,"accession":"0001628280-25-011405","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001628280-25-011405","line_url":"/filing/0001628280-25-011405","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14113.0,"shares_display":"14,113","price_per_share":341.3238577623468,"price_display":"341.32","price_state":"stated","total_value":4817103.6046,"total_display":"4,817,103.60","total_whole":"4,817,104","shares_owned_after":5140.0,"shares_owned_after_display":"5,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider","n_lines":9},{"id":4535716,"accession":"0001628280-25-010224","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-25-010224","line_url":"/filing/0001628280-25-010224","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1227.0,"shares_display":"1,227","price_per_share":341.06605452322736,"price_display":"341.07","price_state":"stated","total_value":418488.0489,"total_display":"418,488.05","total_whole":"418,488","shares_owned_after":3903.0,"shares_owned_after_display":"3,903","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-28","filed_date":"2025-03-04","scope":"insider","n_lines":2},{"id":5110576,"accession":"0001628280-25-002655","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-25-002655","line_url":"/filing/0001628280-25-002655#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":103.0,"shares_display":"103","price_per_share":335.24,"price_display":"335.24","price_state":"stated","total_value":34529.72,"total_display":"34,529.72","total_whole":"34,530","shares_owned_after":4955.0,"shares_owned_after_display":"4,955","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-27","scope":"insider"},{"id":4290983,"accession":"0001628280-25-001900","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-25-001900","line_url":"/filing/0001628280-25-001900#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":442.0,"shares_display":"442","price_per_share":273.41,"price_display":"273.41","price_state":"stated","total_value":120847.22,"total_display":"120,847.22","total_whole":"120,847","shares_owned_after":5058.0,"shares_owned_after_display":"5,058","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-17","filed_date":"2025-01-17","scope":"insider"},{"id":2117089,"accession":"0000950170-24-075221","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-075221","line_url":"/filing/0000950170-24-075221#line-2","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":280.0,"price_display":"280.00","price_state":"stated","total_value":532000.0,"total_display":"532,000.00","total_whole":"532,000","shares_owned_after":5500.0,"shares_owned_after_display":"5,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-14","filed_date":"2024-06-18","scope":"insider"},{"id":2177230,"accession":"0000950170-24-073969","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-073969","line_url":"/filing/0000950170-24-073969#line-2","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":285.0,"price_display":"285.00","price_state":"stated","total_value":570000.0,"total_display":"570,000.00","total_whole":"570,000","shares_owned_after":5500.0,"shares_owned_after_display":"5,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-12","filed_date":"2024-06-14","scope":"insider"},{"id":2588448,"accession":"0000950170-24-064271","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-064271","line_url":"/filing/0000950170-24-064271#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1036.0,"shares_display":"1,036","price_per_share":231.34,"price_display":"231.34","price_state":"stated","total_value":239668.24,"total_display":"239,668.24","total_whole":"239,668","shares_owned_after":5500.0,"shares_owned_after_display":"5,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-21","filed_date":"2024-05-23","scope":"insider"},{"id":8576928,"accession":"0000950170-23-071116","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-23-071116","line_url":"/filing/0000950170-23-071116","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":238.5,"price_display":"238.50","price_state":"stated","total_value":477000.0,"total_display":"477,000.00","total_whole":"477,000","shares_owned_after":5667.0,"shares_owned_after_display":"5,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-15","filed_date":"2023-12-18","scope":"insider","n_lines":2},{"id":8576919,"accession":"0000950170-23-071116","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-071116","line_url":"/filing/0000950170-23-071116","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":232.5,"price_display":"232.50","price_state":"stated","total_value":465000.0,"total_display":"465,000.00","total_whole":"465,000","shares_owned_after":6667.0,"shares_owned_after_display":"6,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-14","filed_date":"2023-12-18","scope":"insider","n_lines":2},{"id":8621259,"accession":"0000950170-23-070416","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-23-070416","line_url":"/filing/0000950170-23-070416","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":225.4,"price_display":"225.40","price_state":"stated","total_value":563500.0,"total_display":"563,500.00","total_whole":"563,500","shares_owned_after":6667.0,"shares_owned_after_display":"6,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-13","filed_date":"2023-12-14","scope":"insider","n_lines":2},{"id":8621254,"accession":"0000950170-23-070416","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-070416","line_url":"/filing/0000950170-23-070416","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":217.84615384615384,"price_display":"217.85","price_state":"stated","total_value":283200.0,"total_display":"283,200.00","total_whole":"283,200","shares_owned_after":5667.0,"shares_owned_after_display":"5,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-12","filed_date":"2023-12-14","scope":"insider","n_lines":2},{"id":7799671,"accession":"0000899243-23-006751","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-23-006751","line_url":"/filing/0000899243-23-006751","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":274.416272,"price_display":"274.42","price_state":"stated","total_value":1372081.36,"total_display":"1,372,081.36","total_whole":"1,372,081","shares_owned_after":8739.0,"shares_owned_after_display":"8,739","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-02","scope":"insider","n_lines":4},{"id":7799659,"accession":"0000899243-23-006751","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-006751","line_url":"/filing/0000899243-23-006751","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001876996","owner_name":"Waltermire Robert E.","owner_display_name":"Waltermire Robert E.","owner_url":"/insider/0001876996","role":"Officer (Senior VP, Chief Pharma Dev)","role_mark":"O","role_mark_label":"Officer (Senior VP, Chief Pharma Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Chief Pharma Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":272.0714,"price_display":"272.07","price_state":"stated","total_value":1360357.0,"total_display":"1,360,357.00","total_whole":"1,360,357","shares_owned_after":5667.0,"shares_owned_after_display":"5,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-28","filed_date":"2023-03-02","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":30,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":30,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":30},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"MADRIGAL PHARMACEUTICALS, INC.","url":"/issuer/0001157601","role":"Officer (Senior VP, Chief Pharma Dev)","n_filings":10,"first_seen":"2023-03-02","last_seen":"2025-03-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001876996","retrieved_at":"2026-08-25T21:38:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}